Simulations Plus reported a 9% increase in total revenue in Q3 2023, driven by its software segment. However, declining gross margins and rising operational costs could impact future profitability.

Simulations Plus SLP recently announced that the FDA (United States Food and Drug Administration) has renewed its DILIsym software licenses for the seventh year in a row. DILIsym is a modernized ...

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and ...

Simulations Plus ( (SLP)) has released its Q1 earnings. Here is a breakdown of the information Simulations Plus presented to its investors. Simulations Plus, Inc., a prominent entity in the biopharma ...

Simulations Plus is benefiting from the growing use of computational tools in drug discovery, which would be boosted by the FDA Modernization Act 2.0. The biosimulation market is highly fragmented and ...

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced ...

Expert panel at the 2026 ASCPT Annual Meeting brings together leaders with industry and regulatory experience to explore practical, accountable AI implementationRESEARCH TRIANGLE PARK, N.C.--(BUSINESS ...

Screen: Pro-ficiency creates clinical trial simulations, filling a gap for the Simulations Plus suite of products. So far, 2024 is shaping up to be a banner year for Simulations Plus Inc. The ...

Simulations Plus (NASDAQ:SLP) will release its quarterly earnings report on Monday, 2025-12-01. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Simulations Plus to ...

Conestoga Capital Advisors, an asset management company, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equity markets continued their momentum that ...

Simulations Plus, Inc. (NASDAQ:SLP) is one of the Best Beaten Down Stocks to Buy Now. KeyBanc downgraded the company’s stock to “Sector Weight” from “Overweight” without a price target, as reported by ...

Webcast links will be available on the Investor Relations section of our website. For more information about the events or questions about registration, interested parties should reach out to their ...